odronextamab
Selected indexed studies
- Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. (Ann Oncol, 2024) [PMID:39147364]
- Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. (Blood Adv, 2025) [PMID:40472301]
- Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. (Lancet Haematol, 2022) [PMID:35366963]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. (2025) pubmed
- Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. (2024) pubmed
- Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. (2022) pubmed
- Odronextamab: First Approval. (2024) pubmed
- Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. (2025) pubmed
- Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. (2025) pubmed
- Antibodies to watch in 2025. (2025) pubmed
- Odronextamab against relapsed or refractory follicular lymphoma. (2024) pubmed
- New bispecific antibodies in diffuse large B-cell lymphoma. (2025) pubmed
- Bispecific antibodies in follicular lymphoma. (2025) pubmed